Skip to main content
PLOS One logoLink to PLOS One
. 2021 Jan 13;16(1):e0244116. doi: 10.1371/journal.pone.0244116

Exercise modifies glutamate and other metabolic biomarkers in cerebrospinal fluid from Gulf War Illness and Myalgic encephalomyelitis / Chronic Fatigue Syndrome

James N Baraniuk 1,*, Grant Kern 1, Vaishnavi Narayan 1, Amrita Cheema 2
Editor: Pankaj K Singh3
PMCID: PMC7806361  PMID: 33440400

Abstract

Myalgic encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) and Gulf War Illness (GWI) share many symptoms of fatigue, pain, and cognitive dysfunction that are not relieved by rest. Patterns of serum metabolites in ME/CFS and GWI are different from control groups and suggest potential dysfunction of energy and lipid metabolism. The metabolomics of cerebrospinal fluid was contrasted between ME/CFS, GWI and sedentary controls in 2 sets of subjects who had lumbar punctures after either (a) rest or (b) submaximal exercise stress tests. Postexercise GWI and control subjects were subdivided according to acquired transient postexertional postural tachycardia. Banked cerebrospinal fluid specimens were assayed using Biocrates AbsoluteIDQ® p180 kits for quantitative targeted metabolomics studies of amino acids, amines, acylcarnitines, sphingolipids, lysophospholipids, alkyl and ether phosphocholines. Glutamate was significantly higher in the subgroup of postexercise GWI subjects who did not develop postural tachycardia after exercise compared to nonexercise and other postexercise groups. The only difference between nonexercise groups was higher lysoPC a C28:0 in GWI than ME/CFS suggesting this biochemical or phospholipase activities may have potential as a biomarker to distinguish between the 2 diseases. Exercise effects were suggested by elevation of short chain acylcarnitine C5-OH (C3-DC-M) in postexercise controls compared to nonexercise ME/CFS. Limitations include small subgroup sample sizes and absence of postexercise ME/CFS specimens. Mechanisms of glutamate neuroexcitotoxicity may contribute to neuropathology and “neuroinflammation” in the GWI subset who did not develop postural tachycardia after exercise. Dysfunctional lipid metabolism may distinguish the predominantly female ME/CFS group from predominantly male GWI subjects.

Introduction

Myalgic encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) [13] and Gulf War Illness (GWI) [47] share many symptoms of fatigue, pain, and cognitive dysfunction that are not relieved by rest. Exerting more physical, cognitive, emotional or other effort than usual leads to symptom exacerbation that may be delayed 24 hr or more in onset, and that is not relieved by rest; this has been termed post-exertional malaise or exertional exhaustion. ME/CFS has a sporadic incidence and predominantly affects females (4:1), while GWI affects 25% to 32% of the cohort of predominantly male personnel exposed to conditions in the Persian Gulf in 1990–1991. The overlap in subjective symptoms and criteria highlights the need for objective biomarkers to advance understanding of pathophysiological mechanisms, improve diagnostics that distinguish between the two diseases, and develop specific treatment strategies.

Metabolomics alterations have been found in the brain [8] and peripheral blood from ME/CFS [919] and GWI subjects [20, 21]. The patterns of change in amino acids, glycolysis, fatty acids, and other mediators implicate mitochondrial dysfunction that may affect glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pyruvate dehydrogenase and its inhibitors, transport of metabolites across the mitochondrial membranes, interruption of electron transport chain complexes, or peroxisomal metabolism of very long chain polyunsaturated fatty acids. The molecular details responsible for dysfunction remain to be defined for each disease.

Metabolomic profiles in cerebrospinal fluid were assessed as part of a larger analysis of proteomic [22], neuropeptide [2325], miRNA [26] and other biomarker alterations in ME/CFS and GWI compared to sedentary control (SC) subjects.

Lumbar punctures were performed in 2 settings in different groups of participants. First, “nonexercise” subjects rested overnight before history and physical, phlebotomy and lumbar puncture (nonexercise groups abbreviated as sc0, cfs0 and gwi0) [26]. Second, a model of exertional exhaustion was developed by having subjects perform submaximal bicycle exercise on 2 consecutive days with functional magnetic resonance imaging (fMRI) studies performed at baseline and after the stress tests [2733]. Lumbar puncture was performed after the post-exercise MRI in sedentary control (SC) and GWI subjects.

GWI subjects were subdivided into 2 groups based on transient postural tachycardia that developed after exercise. One third of participants developed postural tachycardia after exercise because their heart rates rose by ≥30 beats per minute after standing up [27, 34, 35]. They were termed the Stress Test Activated Reversible Tachycardia (START) phenotype. This response was significantly different from Postural Orthostatic Tachycardia Syndrome (POTS) [36, 37] because START had normal elevations of 10 to 15 beats per minute before exercise, then transient postural tachycardia for 1 to 3 days after exercise.

The other two thirds of GWI subjects had normal postural heart rate elevations at all times, and significant patterns of fMRI changes following exercise that were reminiscent of phantom limb and other pain syndromes [38, 39] and significantly different from START and controls; this GWI subset was called the Stress Test Originated Phantom Perception (STOPP) phenotype. The post-exercise groups were abbreviated in capitals as SC, START and STOPP for comparison to the nonexercise groups.

The START phenomenon was also induced by exercise in ME/CFS and control groups [34, 35]. However, START versus STOPP status was not associated with postexercise changes in fMRI in control or ME/CFS [3133].

Cerebrospinal fluid metabolomics data were assessed for differences between nonexercise (sc0, cfs0 and gwi0) and postexercise (SC, GWI START and STOPP) groups, and between post-exercise and appropriate nonexercise controls (SC vs. sc0, START vs. gwi0, STOPP vs. gwi0). Nonexercise subjects could not be assigned into START or STOPP phenotypes because exercise is necessary to induce the defining postural tachycardia. No post-exercise ME/CFS cerebrospinal fluid specimens were available for this pilot investigation.

Methods

Subjects

Protocols were approved by the Georgetown University Institutional Review Board (2006–481, 2009–229, 2013–0943, 2015–0579) and USAMRMC Human Research Protection Office (HRPO #A-15547, A-18479), and listed in clinicaltrials.gov (NCT01291758, NCT00810225, NCT03342482).

Healthy and Gulf War Illness (GWI) veterans from the 1990–1991 Persian Gulf War, ME/CFS, and healthy, non-military control subjects were recruited from websites, word of mouth, fliers, newspaper and online advertisements, and personal contacts in clinics and support groups. Interested participants responded via telephone or email. After obtaining verbal consent, each volunteer had an initial telephone screening with a clinical research associate who read a scripted outline of the study to assess inclusion and exclusion criteria. Candidates were screened for military service in the Gulf War Theater; Center for Disease Control (CDC) criteria for Chronic Multisymptom Illness (CMI) [5] and Chronic Fatigue Syndrome (CFS) [1]; Kansas criteria for GWI [6]; current medications; chronic medical and psychiatric illnesses [4042]. Eligible subjects came to the Georgetown Howard Universities Clinical and Translational Science Clinical Research Unit where diagnosis and study inclusion were confirmed by history and physical examination.

GWI was defined by moderate to severe scores for (a) ≥2 out of 3 CMI criteria (fatigue, mood-cognition, and musculoskeletal pain) [5] plus (b) ≥3 out of 6 symptom domains of the Kansas criteria (fatigue/sleep, pain, neurological/cognitive/mood, gastrointestinal, respiratory, skin) [6, 7, 43].

ME/CFS was defined using 1994 CDC “Fukuda” criteria [1] plus Canadian Consensus Criteria [2, 3]. The CDC criteria require disabling fatigue lasting more than 6 months that cannot be explained by exclusionary medical or psychiatric diagnoses [810] plus at least 4 of 8 ancillary symptoms: short term memory of concentration problems, sore throat, sore lymph nodes, myalgia, arthralgia, headache, sleep disturbance, and post-exertional malaise (exertional exhaustion). The Carruthers Canadian Consensus Criteria emphasized fatigue, postexertional malaise, sleep, pain, cognition, and added an array of flu-like, autonomic and interoceptive symptoms [2, 3]. Subjects were not assessed for 2015 Institute of Medicine criteria for Systemic Exertion Intolerance Disease (SEID) with fatigue, postexertional malaise, sleep and either cognitive or orthostatic problems [44].

Sedentary controls in the nonexercise (sc0) and postexercise (SC) groups had a sedentary lifestyle with less than 40 min of aerobic exercise per week and did not meet ME/CFS, CMI or Kansas criteria.

Exclusion criteria included substance abuse, hospitalization for a psychiatric disorder in the past 5 years, or a chronic medical or psychiatric condition not related to service in the Persian Gulf [4042].

Two cohorts were studied. The first day of the 2 protocols was considered an adjustment period, and included the patient’s history and physical, blood work, and baseline studies. The first “nonexercise” cohort rested before having lumbar puncture, and were termed sc0, cfs0 and gwi0 groups. They did not have exercise.

The second “postexercise” cohort had magnetic resonance imaging (MRI), submaximal bicycle exercise stress testing, and serial assessments of postural tachycardia. They rested overnight, then had their second identical stress test, MRI and “postexercise” lumbar puncture. Subjects cycled at 70% of predicted heart rate (pHR = 220-Age) for 25 min then increased to 85% pHR. Exercise-induced postural tachycardia defined two subgroups of GWI veterans [27, 34]. Exercise was required to define START vs. STOPP phenotypes. The post-exercise sedentary control group was termed SC.

Lumbar puncture

Identical methods were used in all subjects. Cerebrospinal fluid (20 ml) was drawn from the L1-L2 interspace using Gertie-Marx needles [45, 46] in the prone position under fluoroscopic guidance by interventional radiologists. Specimens were immediately placed on ice, centrifuged at 4°C, specimens sent for routine laboratory studies, and aliquoted and stored at -80°C within 1 hr. After lumbar puncture subjects were informed strictly to rest in comfortable positions and to avoid straining actions and Valsalva maneuvers such as lifting luggage for 24 hr before discharge.

Metabolomics

Biocrates AbsoluteIDQ® p180 kit was employed according to manufacturer’s instructions to detect amino acids (n = 21), biogenic amines (n = 21), total hexoses, acylcarnitines (n = 40), lysophosphatidylcholines (n = 14), phosphatidylcholines (n = 76), and sphingolipids (n = 15) [4749]. Frozen (-80°C) deidentified cerebrospinal fluid specimens were analyzed in blinded fashion by adding specimens (35 μL) and internal standard solution (10 μL) to wells of each 96-well extraction plate. Low, medium and high quality control samples, blank, zero sample, and calibration standards were added to appropriate wells. The plate was dried under a gentle stream of nitrogen. Samples were derivatized with phenyl isothiocyanate to detect amino acids and biogenic amines, then extracted with 5mM ammonium acetate in methanol before being diluted 15:1 with 40% methanol in water for the UPLC-MS/MS analysis of amino acids and amines, and 20:1 with proprietary kit running solvent for flow injection analysis (FIA) mass spectrometry of acylcarnitines, sphingolipids and glycerophospholipids.

Chromatographic separation of amino acids and biogenic amines and their stable-isotope labeled internal standards was performed on a ACQUITY UPLC System (Waters Corporation) using a ACQUITY 2.1 mm x 50 mm 1.7 μm BEH C18 column fitted with a ACQUITY BEH C18 1.7 μm VanGuard guard column, and quantified by calibration curve using a linear and quadratic regression with 1/x weighting [50, 51]. Eluates from UPLC and FIA were introduced directly into positive electrospray ionization device and Xevo TQ-S mass spectrometer (Waters Corporation) operating in the Multiple Reaction Monitoring (MRM) mode. MRM transitions (compound-specific precursor to product ion transitions) for each analyte and its internal standard were collected over the appropriate retention time using tune files and acquisition methods provided in the AbsoluteIDQ® p180 Standard Operating Procedures [47]. The UPLC data were imported into TargetLynx (Waters Corporation) for peak integration, calibration and concentration calculations (μM). Peaks were quantified using FIA and the processed TargetLynx data and Biocrates’ Workflow Manager MetIDQ™ system. Data were analyzed without imputation for levels at or below the lower limits of detection. Lipids were named using LIPID MAPS Structure Database [5053] to identify potential isobaric (± 0.5 Da) and isometric lipid species.

Statistical and bioinformatic analysis

The primary variable of interest for general linear regression was the group identifier in order to find significant differences between sc0, cfs0, gwi0, SC, START and STOPP groups. Gender, body mass index (BMI), and age have been associated with specific metabolites in previous studies [5456] and these variables and their cross-products were incorporated into the models. Group differences in cerebrospinal fluid metabolite concentrations were assessed by ANOVA with Tukey Honest Significant Difference tests to correct for multiple comparisons (SPSS24 software). Effect sizes were estimated with Hedges’ g [57]. Pearson correlations, principal component analysis (PCA), and t-distributed stochastic neighbor embedding (t-SNE) analysis [58] (R Studio Rtsne package) [59] were performed to check for collinearity, possible technical artifacts and any other unusual patterns.

The primary raw data are provided in S1 Raw data.

Results

Study candidates (n = 442) were extensively screened (Table 1). The 116 inpatient study participants were predominantly white (n = 103) and non-Hispanic (n = 109) (Table 2) [60]. Five of the seven post-exercise SC subjects were deployed Persian Gulf War veterans. The high symptom load in ME/CFS and GWI was confirmed by the “floor” effects of sc0 and SC groups compared to the elevated “ceiling” effects for symptom scores and disabling (lower) quality of life scores in cfs0, gwi0, START and STOPP (Table 2).

Table 1. CONSORT information [60].

Study protocol Nonexercise lumbar puncture Exercise protocol followed by lumbar puncture
Subjects recruited Sedentary control (sc0) Sedentary control (SC)
CFS (cfs0) GWI START phenotype was defined by postural tachycardia after exercise. STOPP had no postural tachycardia.
GWI (gwi0)
Contacted 271 171
Screened 123 96
Medical exclusions 13 16
Declined to participate 24 51
Lumbar puncture 86 (57 female) 30 (4 female)
Groups and N (N females)
sc0 21 (10 female) 0
cfs0 45 (36 female) 0
gwi0 20 (11 female) 0
SC 0 7 (0 female)
START phenotype of GWI 0 7 (1 female)
STOPP phenotype of GWI 0 16 (3 female)
Total 116 (61 female)

Table 2. Demographics.

Nonexercise Post-exercise
sc0 cfs0 gwi0 SC START STOPP
n (female) 21 (10) 45 (36) 20 (11) 7 (0) 7 (1) 16 (3)
Age 42.3±5.6 45.6±3.1 48.9±4.4 50.1±5.9 45.1±7.6 44.7±3.2
BMI 27.0±2.3 28.8±2.1 30.8±2.3 30.0±2.1 29.0±4.0 29.7±2.7
CFSQ
    fatigue 1.2±0.6 3.7±0.2 3.5±0.2 1.1±0.5 3.6±0.4 3.5±0.3
    memory 1.0±0.5 3.1±0.2 2.8±0.4 1.0±0.9 3.0±0.7 2.8±0.4
    sore throat 0.4±0.3 1.4±0.4* 1.4±0.5 0.1±0.3 2.4±0.6 1.5±0.6*
    sore nodes 0.2±0.3 1.3±0.4 1.6±0.7 0.0±0.0 2.0±1.0 1.2±0.5
    muscle pain 1.2±0.6 2.9±0.4 3.2±0.5 0.9±0.5 3.3±0.4 3.1±0.5
    joint pain 0.8±0.4 2.6±0.4 2.8±0.6 1.1±0.7 3.0±1.0 3.3±0.4
    headaches 0.7±0.5 2.5±0.4 2.5±0.5 1.1±1.1 3.1±0.9 2.7±0.6
    sleep 1.4±0.7 3.5±0.3 3.5±0.3 1.9±0.9 3.4±0.4 3.6±0.5
    exertional exhaustion 1.2±0.7 3.4±0.3 3.2±0.6 0.4±0.6 3.6±0.4 3.2±0.5
Sum of 8 CFS ancillary criteria scores 7.0±3.1 20.7±1.3 20.9±2.4 6.6±3.1 24.1±3.1 21.5±2.8
SF-36
    Physical functioning 85.5±10.1 41.5±6.8 42.2±12.6 80.0±21.3 43.6±22.6 46.1±12.5
    Role physical 65.5±19.6 6.3±5.8 9.7±9.0 89.3±14.6 0.0±0.0 19.6±17.9
    Bodily pain 78.2±13.2 32.4±5.9 37.6±12.3 70.9±16.2 19.7±12.7 30.4±10.8
    General health 71.4±7.8 34.5±6.0 28.1±7.8 75.3±8.8 13.9±8.7 31.3±11.5
    Vitality 57.4±12.2 12.1±3.5 22.2±6.2 65.7±11.2 15.0±8.8 15.0±7.7
    Social functioning 82.1±12.1 25.0±6.7 29.9±11.2 85.7±12.5 16.1±12.8 33.0±11.1
    Role emotional 82.5±14.7 58.3±14.0 25.9±18.0 90.5±18.7 4.8±9.3 35.7±23.2
    Mental health 77.9±4.8 64.2±5.4 51.1±10.9 74.9±12.4 41.1±15.9 55.4±9.1
IgG/Albumin 0.124 ±0.019 0.113 ±0.012 0.124 ±0.013 0.122 ±0.018 0.112 ±0.022 0.114 ±0.019

*p<0.05 and

†p<0.01 vs. sc0 and SC, and

¶p<0.05 vs. cfs0 by Tukey Honest Significant Difference.

mean ± 95% CI.

Pearson correlations were assessed between the concentrations of all 180 metabolites in each of the 6 groups (Fig 1, S1 to S6 Tables). Phospholipids from all classes had the highest Pearson correlations in SC and sc0. Amino acids had relatively high correlations in START, sc0, SC and gwi0 (p > 0.8). SC had negative correlations between several amino acids and carnitines (p < -0.5). Only START had positive correlations between amino acids and phospholipids. Principal component analysis did not reveal any noteworthy relationships between metabolites, disease, groups, exercise, gender or batches.

Fig 1. Pearson correlations between all 180 analytes.

Fig 1

Pearson correlation matrices were depicted for sc0 (A), cfs0 (B), gwi0 (C), SC (D), START (E) and STOPP (F). The line of identify was black. Metabolite classes and legend were color coded (right). Metabolites were arranged in alphabetical order for each class. Each panel is shown in more detail in the S1 to S6 Tables.

t-SNE of the Pearson correlation coefficients between analytes (Fig 1) generated 4 clusters of groups (Fig 2). Nonexercise females and males were separated which was consistent with differences in relative activities of specific metabolic pathways between men and women [5456] that were not influenced by ME/CFS or GWI status. The male-dominated SC, START and STOPP data were separated from nonexercise males suggesting an exercise effect. The postexercise SC group was distinct from the predominantly male GWI START and STOPP groups suggesting an interaction of exercise and GWI status. Gender, exercise and disease effects were factored into general linear modeling (GLM).

Fig 2. t-SNE.

Fig 2

Analysis of the Pearson correlation coefficients between analyte concentrations from the 6 groups (Fig 1) led to clusters of nonexercise females (triangles), nonexercise males (squares), postexercise controls (orange circle), and postexercise START (green circle) and STOPP (red circle) subgroups of GWI subjects.

Glutamate

Glutamate was significantly elevated in the GWI STOPP subgroup compared to nonexercise sc0, cfs0, gwi0, and postexercise START using univariate GLM to correct for subject group, age, gender and BMI (adjusted p = 0.001) followed by ANOVA (p = 0.0020) and Tukey Honest Significant Difference between groups (p≤0.024) (Fig 3). There was no indication of any differences between nonexercise groups, or for a bimodal distribution of glutamate in nonexercise GWI subjects that could have predicted START versus STOPP status. Elevation of glutamate in the postexercise STOPP group suggested effects related to the exertion, GWI as an underlying pathology, and some aspect of the maintenance of the normal postural tachycardia response following exercise. START was equivalent to the nonexercise groups indicating that the elevation of glutamate in STOPP was not directly related to the development of postexertional postural tachycardia. One individual in each of the cfs0, gwi0 and STOPP groups had glutamate levels that were more than the 95th percentiles (2σ) for each group. Removing these subjects did not substantially alter the statistical relationships, and so their data were retained. Hedges’ g was 1.3 for the difference between STOPP and all other data.

Fig 3. Glutamate in cerebrospinal fluid.

Fig 3

Glutamate was significantly higher in STOPP (bright red) than nonexercise sc0 (yellow), cfs0 (light blue), gwi0 (dark red), and postexercise START (green). Females (triangles), males (squares) and group mean ± 95% CI (black bar) were shown for each group. SC had no females (no triangles). The lines above the bars indicate significant Tukey’s tests (p ≤ 0.024). Hedges’ g was 1.3 for STOPP versus all other groups.

SC > sc0. C5-OH (C3-DC-M, 3-hydroxyisovaleryl-carnitine, 2-methyl-3-hydroxybutyryl-carnitine) was significantly higher in SC than sc0 by GLM (p corrected = 0.048; Tukey p = 0.009) indicating an exercise effect in sedentary control subjects (Fig 4). Hedges’ g was 1.36 for SC compared to all other subjects and 1.65 versus sc0.

Fig 4. C5-OH.

Fig 4

C5-OH (C3-DC-M) was higher in SC than other groups by GLM, ANOVA and Tukey tests (p < 0.05).

gwi0 > cfs0. LysoPC a C28:0 was significantly higher in gwi0 than cfs0 by ANOVA and Tukey tests (p = 0.036) (Fig 5). In post hoc analysis, gwi0 was significantly higher than the combination of START and STOPP (all postexercise GWI subjects, 2-tailed, unpaired t-test p = 0.036). Hedges’ g was 0.8 for gwi0 compared to all other subjects.

Fig 5. LysoPC a C28:0.

Fig 5

Levels were higher in nonexercise gwi0 than cfs0. The bar indicates significance by Tukey test (p = 0.036).

Discussion

Glutamate was significantly increased in the GWI STOPP compared to all nonexercise and the postexercise START groups. This result suggests that mechanisms of increased neural excitotoxicity are activated by the exercise stressor in this majority phenotype of GWI. START did not have this change indicating exercise alone was not responsible. Instead, elevated glutamate may have been the result of an interaction of exercise with as yet unknown pathological mechanisms active in the STOPP phenotype. Glutaminergic excitotoxicity is highly relevant for interpreting the benefits of a low glutamate diet in GWI and irritable bowel syndrome [6163].

Cerebrospinal fluid was different from serum where ME/CFS have reduced glutamine, ornithine and glucogenic amino acids [9]. This may be due to the differences in glutamine shuttle, energy metabolism and high oxygen requirements of neurons and glial cells compared to peripheral tissues [64] and disruption of the excitatory: inhibitory balance between glutamate and gamma-aminobutyric acid (GABA) in neural processing [65]. There were no compensatory changes in antioxidant peptides such as carnosine (β-alanyl-histidine) and anserine (β-alanyl-N-methylhistidine). N-acetyl-aspartic acid (NAA) was not altered, but is relevant as a source of acetyl-CoA for myelin lipid synthesis in oligodendrocytes, ATP generation in neuronal mitochondria, and as a precursor for the brain neurotransmitter N-acetylaspartylglutamate that is also an alternative source of glutamate [66]. N-acetylaspartylglutamate is a neuron osmolyte and transmitter for axon-glial signaling [67]. GABA, homocarnosine (GABA-histidine) and N-acetylaspartylglutamate were not measured by the Biocrates panel indicating a need to expand the scope of analytes screened using targeted metabolomics of cerebrospinal fluid.

Acylcarnitine C5-OH (C3-DC-M) was higher in postexercise SC than other groups. This suggested (i) no differences between nonexercise groups, (ii) effects of exercise (SC>sc0) and (iii) differences between postexercise SC and GWI groups.

Steady state nonexercise acylcarnitine levels were equivalent in the 3 nonexercise groups (sc0, cfs0, gwi0). Serum levels of C8:1, C12DC, C14, C16:1, C18, C18:1 (oleyl-L-carnitine), C18:2 (linoleyl-L-carnitine) and C18:1-OH acylcarnitines were significantly lower in ME/CFS (n = 44) than controls (n = 49, p < 0.0001) [68, 69]. Levels were correlated with clinical symptoms [70]. Japanese and Swedish ME/CFS groups had significant reductions after correcting for diet and nationality [71]. Very long-chain acylcarnitines were decreased in veterans with GWI [20, 21]. These data suggest the hypothesis that reduced carnitine palmitoyltransferase-I (CPT-I) activity and mitochondrial fatty acid transport may contribute to the pathogenesis of ME/CFS and GWI, and that appropriate nutrient supplementation may correct the imbalances. However, this hypothesis is controversial as other studies found no differences for total carnitine, free carnitine, acylcarnitine and carnitine esters in 25 female ME/CFS and 25 healthy matched neighbourhood controls [72] nor in plasma and timed urine samples from ME/CFS (n = 31), healthy controls (n = 31), depression (n = 15) and rheumatoid arthritis (n = 22) [73]. Elevated serum and urine C5-OH are indicators of marginal biotin deficiency in humans [74] but this is an unlikely explanation in the postexercise control subjects. Cerebrospinal fluid / plasma ratios for L-carnitine and C3-carnitine, but not C5, were significantly elevated in Alzheimer disease compared to controls [75]. Low intramuscular levels of short-chain acylcarnitines have been found in older females compared to males [76]. Low levels were correlated with reduced physical performance and deficient expression of genes involved in mitochondrial energy production. It is not clear if serum or urine levels correlate with cerebrospinal fluid, if C5-OH, other short chain, moderate and long chain acylcarnitines are altered in parallel, or if differences between radioenzymatic, liquid chromatography, mass spectrometry and nuclear magnetic resonance methods may account for some of the diversity of outcomes.

The exercise protocol of 25 minutes of submaximal bicycling at 70% predicted maximum heart rate was comparable to studies with 30 min duration at 40% to 45% of VO2MAX that rapidly activate muscular work, lipolysis, robust fatty acid oxidation [77], and elevate short chain acylcarnitines in plasma [78] while minimizing the contribution from liver β-oxidation [79]. Higher C5-OH in postexercise SC than sc0 would be consistent with this metabolic exercise effect. However, plasma metabolites were not measured and we have not established whether the source of cerebrospinal fluid acylcarnitines was flux across blood-brain barriers from plasma or production by central nervous system neurons or glial cells. In contrast, there were no differences in carnitines between nonexercise gwi0 and postexercise GWI subjects suggesting that exercise did not increase carnitine production by fatty acid oxidation or other pathways in that disease.

The higher C5-OH levels in SC than postexercise GWI supports the contention that GWI subjects had inefficient fatty acid oxidation that did not respond appropriately to the exercise stimulus. Another alternative may be disordered metabolism of leucine or other anaplerotic pathways [19] in muscle, brain or other organs during and after exercise. An unlikely explanation may be differences in timing of meals before lumbar puncture in each group. Caution is needed to not overinterpret the C5-OH results based on the finding that plasma amino acid and acylcarnitine levels can change dynamically within minutes [80, 81].

Only one other lipid was significant. lysoPC a C28:0 was higher in nonexercise gwi0 than cfs0. Further study is needed to determine if this lipid may be a biomarker to differentiate between mechanisms of GWI and ME/CFS. Unlike plasma [20], the sums of concentrations for all carnitine, lysophospholipid, phosphatidylcholine and sphingomyelin lipid families were not significantly different between GWI, ME/CFS, control, or exercise groups.

There are significant limitations to interpretation of this pilot study. The nonexercise and postexercise sets of cerebrospinal fluid were collected at different times with different lots of lumbar puncture kits. Lumbar punctures were performed between 1 and 4 pm, so the timing of lunch and the postprandial time periods may differ between postexercise and nonexercise subjects leading to differences in circulating nutrients, gut metabolites, hormones, and fluids. Different groups of nonexercise and postexercise subjects were tested in parallel because time course studies of individuals who had lumbar punctures before and immediately after exercise would have had high risks for postexertional Valsalva-related spinal headaches. Sample collection was standardized, but prolonged storage may have allowed alteration of analyte concentrations and stoichiometry even though some compounds such as carnitines are reported to be stable indefinitely when stored at -80°C [82]. Cerebrospinal fluid originates as a plasma exudate through choroid plexus epithelial cells with alteration of metabolite mixes by neurons and glia. The contributions and mechanisms of release from each cellular source cannot be directly traced in these subjects.

The Biocrates kit cannot differentiate lipids attached to the glycerol backbone in sn-1 versus sn-2 positions or positions of acyl versus alkyl bonds. The standards provide the total number of carbon atoms and double bonds but cannot distinguish between different isomers (same molecular weight but different chemical structures), isobars (same nominal mass using most abundant isotopes, but with different exact masses), relative lengths of chains at either location, or the exact positions of double bonds. Sphingomyelins are named based on the adduct to the amide bond and its numbers of carbon atoms, double bonds and presence or absence of a hydroxyl group with the assumption that the backbone was sphingosine d18:0. Many other side chains were possible at this position, and would have to be identified using untargeted metabolomics strategies. Phosphocholines and lysophosphocholines with alkyl and ether linkages were investigated, but the positions of the ether links were not specified. Other lipid classes identified from the head groups such as ethanolamine and inositol phosphatides, sulfotides, and glycophospholipids were not characterized. Quantification of these lipids will require future studies with orthogonal detection and characterization (e.g. nuclear magnetic resonance), larger test sets, and spiking with predefined pure compounds. The scope of chemicals will also need to be expanded to include oxidized and nitrosylated markers of reactive free radicals such as 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA), peroxidation of polyunsaturated fatty acids (PUFAs) such as linoleic, arachidonic, and docosahexaenoic acids that contain the highly susceptible (1Z, 4Z) pentadiene moiety [83].

The STOPPSTART dichotomy in GWI was associated with differences in postexercise cerebrospinal fluid glutamate (Fig 1), miRNA [26] and differential activation of cerebellar and other brain regions by fMRI [3133]. This dichotomy does not appear to be as influential in ME/CFS or control subsets. Additional work is required to deconstruct these processes into their component parts and to develop new mechanistic hypotheses to explain the exercise-induced consequences.

Conclusion

Glutamate was elevated in the GWI STOPP phenotype suggesting the hypothesis that these subjects have neuroexcitotoxicity as a component of postexertional malaise and exertional exhaustion. Future studies are required to determine if cerebrospinal fluid levels of glutamate become elevated in the postexercise STOPP subset of ME/CFS or if this change is limited to GWI. Exertional stressors may exacerbate dysfunctional brainstem autonomic control systems, astrocytes, amino acid metabolism and mitochondrial energy production. Hedges’ g suggests the elevated glutamate measurement should be reproducible if the testing paradigm is repeated or the samples assayed with independent methods. Lyso PC a C28:0 may differentiate ME/CFS from GWI. C5-OH was elevated in the postexercise control group and may be a marker of exercise effects. These findings are consistent with hypotheses of dysfunctional amino acid and mitochondrial energy production, lipid and peroxisome metabolism with changes in carnitines, phospholipase enzyme activities, lysophospholipids and polyunsaturated fatty acids in ME/CFS [819, 6873] and GWI [20, 21].

Supporting information

S1 Raw data

(XLSX)

S1 Table

(XLSX)

S2 Table

(XLSX)

S3 Table

(XLSX)

S4 Table

(XLSX)

S5 Table

(XLSX)

S6 Table

(XLSX)

Data Availability

The minimal data sets are attached as Excel sheets in the Supporting Information files.

Funding Statement

JNB: W81XWH-15-1-0679, W81-XWH-09-1-0526, R21NS088138, R01NS085131. Department of Defense. https://cdmrp.army.mil/funding National Institute of Neurological Diseases and Stroke. https://www.ninds.nih.gov/ The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121: 953–959. 10.7326/0003-4819-121-12-199412150-00009 [DOI] [PubMed] [Google Scholar]
  • 2.Carruthers B M, Jain A K, De Meirleir K L. et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr 2003;11: 7–115. [Google Scholar]
  • 3.Carruthers BM. Definitions and aetiology of myalgic encephalomyelitis: how the Canadian consensus clinical definition of myalgic encephalomyelitis works. J Clin Pathol. 2007;60: 117–119. 10.1136/jcp.2006.042754 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Research Advisory Committee on Gulf War Veterans’ Illnesses. Gulf War Illness and the Health of Gulf War Veterans Scientific Findings and Recommendations. 2008. https://www.va.gov/RAC-GWVI/docs/Committee_Documents/GWIandHealthofGWVeterans_RAC-GWVIReport_2008.pdf. Accessed 29 Jan 2017.
  • 5.Fukuda K, Nisenbaum R, Stewart G, Thompson WW, Robin L, Washko RM, et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA. 1998;280: 981–988. 10.1001/jama.280.11.981 [DOI] [PubMed] [Google Scholar]
  • 6.Steele L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am J Epidemiol. 2000;152: 992–1002. 10.1093/aje/152.10.992 [DOI] [PubMed] [Google Scholar]
  • 7.Institute of Medicine. Chronic Multisymptom Illness in Gulf War Veterans: Case Definitions Reexamined. National Academies Press (US), Washington DC: 2014. 10.17226/18623 [DOI] [PubMed] [Google Scholar]
  • 8.Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S, Dyke JP, et al. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. 2012;25: 1073–1087. 10.1002/nbm.2772 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Armstrong CW, McGregor NR, Sheedy JR, Buttfield I, Butt HL, Gooley PR. NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue syndrome. Clin Chim Acta. 2012;413: 1525–1531. 10.1016/j.cca.2012.06.022 [DOI] [PubMed] [Google Scholar]
  • 10.Armstrong CW, McGregor NR, Butt HL, Gooley PR. Metabolism in chronic fatigue syndrome. Adv Clin Chem. 2014;66: 121–172. 10.1016/b978-0-12-801401-1.00005-0 [DOI] [PubMed] [Google Scholar]
  • 11.Naviaux RK, Naviaux JC, Li K, Bright AT, Alaynick WA, Wang L, et al. Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci U S A. 2016;113: E5472–80. 10.1073/pnas.1607571113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Yamano E, Sugimoto M, Hirayama A, Kume S, Yamato M, Jin G, et al. Index markers of chronic fatigue syndrome with dysfunction of TCA and urea cycles. Sci Rep. 2016;6: 34990 10.1038/srep34990 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Germain A, Ruppert D, Levine SM, Hanson MR. Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. Mol Biosyst. 2017;13: 371–379. 10.1039/c6mb00600k [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Tomas C, Brown A, Strassheim V, Elson JL, Newton J, Manning P. Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. PLoS One. 2017;12: 10.1371/journal.pone.0186802 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Tomas C, Newton J. Metabolic abnormalities in chronic fatigue syndrome/myalgic encephalomyelitis: a mini-review. Biochem Soc Trans. 2018;46: 547–553. 10.1042/BST20170503 [DOI] [PubMed] [Google Scholar]
  • 16.Malatji BG, Meyer H, Mason S, Engelke UFH, Wevers RA, van Reenen M, et al. A diagnostic biomarker profile for fibromyalgia syndrome based on an NMR metabolomics study of selected patients and controls. BMC Neurol. 2017;17:88 10.1186/s12883-017-0863-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Wallis A, Butt H, Ball M, Lewis DP, Bruck D. Support for the microgenderome invites enquiry into sex differences. Gut Microbes. 2017;8: 46–52. 10.1080/19490976.2016.1256524 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Nagy-Szakal D, Barupal DK, Lee B, Che X, Williams BL, Kahn EJR, et al. Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics. Sci Rep. 2018;8: 10056 10.1038/s41598-018-28477-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Fluge Ø, Mella O, Bruland O, Risa K, Dyrstad SE, Alme K, et al. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight. 2016;1: e89376 10.1172/jci.insight.89376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Emmerich T, Zakirova Z, Klimas N, Sullivan K, Shetty AK, Evans JE, et al. Phospholipid profiling of plasma from GW veterans and rodent models to identify potential biomarkers of Gulf War Illness. PLoS One. 2017;12: e0176634 10.1371/journal.pone.0176634 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Abdullah L, Evans JE, Joshi U, Crynen G, Reed J, Mouzon B, et al. Translational potential of long-term decreases in mitochondrial lipids in a mouse model of Gulf War Illness. Toxicology. 2016;372: 22–33. 10.1016/j.tox.2016.10.012 [DOI] [PubMed] [Google Scholar]
  • 22.Baraniuk JN, Casado B, Maibach H, Clauw DJ, Pannell LK, Hess SS. A Chronic Fatigue Syndrome—related proteome in human cerebrospinal fluid. BMC Neurol. 2005;5: 22 10.1186/1471-2377-5-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Baraniuk JN, Maibach H, Whalen G, Clauw DJ. Covariates of corticotropin-releasing hormone (CRH) concentrations in cerebrospinal fluid (CSF) from healthy humans. BMC Neurosci. 2004;5: 58 10.1186/1471-2202-5-58 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Baraniuk JN, Whalen G, Cunningham J, Clauw DJ. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord. 2004;5: 48 10.1186/1471-2474-5-48 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.McLean SA, Williams DA, Stein PK, Harris RE, Lyden AK, Whalen G, et al. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology. 2006;31: 2776–2782. 10.1038/sj.npp.1301200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Baraniuk JN, Shivapurkar N. Exercise—induced changes in cerebrospinal fluid miRNAs in Gulf War Illness, Chronic Fatigue Syndrome and sedentary control subjects. Sci Rep. 2017;7: 15338 10.1038/s41598-017-15383-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rayhan RU, Stevens BW, Raksit MP, Ripple JA, Timbol CR, Adewuyi O, et al. Exercise challenge in Gulf War Illness reveals two subgroups with altered brain structure and function. PLoS One. 2013;8: e63903 10.1371/journal.pone.0063903 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Clarke T, Jamieson JD, Malone P, Rayhan RU, Washington S, VanMeter JW, et al. Connectivity differences between Gulf War Illness (GWI) phenotypes during a test of attention. PLoS One. 2019;14: e0226481 10.1371/journal.pone.0226481 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Washington SD, Rayhan RU, Garner R, Provenzano D, Zajur K, Addiego FM, et al. Exercise alters cerebellar and cortical activity related to working memory in phenotypes of Gulf War Illness. Brain Comms. 2020;2: fcz039 10.1093/braincomms/fcz039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Provenzano D, Washington SD, Rao YJ, Loew M, Baraniuk JN. Logistic Regression Algorithm Differentiates Gulf War Illness (GWI) Functional Magnetic Resonance Imaging (fMRI) Data from a Sedentary Control. Brain Sci. 2020;10: E319 10.3390/brainsci10050319 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Washington SD, Rayhan RU, Garner R, Provenzano D, Zajur K, Addiego FM, et al. Exercise alters midbrain, cerebellar, and cerebral activation during cognitive testing in Gulf War Illness and Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS). Brain Communications 2020;2: fcaa070 10.1093/braincomms/fcaa070 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Provenzano D, Washington SD, Baraniuk JN. A Machine Learning Approach to the Differentiation of Functional Magnetic Resonance Imaging Data of Chronic Fatigue Syndrome (CFS) From a Sedentary Control. Front Comput Neurosci. 2020;14: 2 10.3389/fncom.2020.00002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Provenzano D, Washington SD, Rao YJ, Loew M, Baraniuk J. Machine Learning Detects Pattern of Differences in Functional Magnetic Resonance Imaging (fMRI) Data between Chronic Fatigue Syndrome (CFS) and Gulf War Illness (GWI). Brain Sci. 2020;10: 456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Garner RS, Rayhan RU, Baraniuk JN. Verification of exercise-induced transient postural tachycardia phenotype in Gulf War Illness. Am J Transl Res. 2018;10: 3254–3264. [PMC free article] [PubMed] [Google Scholar]
  • 35.Garner R, Baraniuk JN. Orthostatic intolerance in chronic fatigue syndrome. J Transl Med. 2019;17: 185 10.1186/s12967-019-1935-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Sheldon RS, Grubb BP 2nd, Olshansky B, Shen WK, Calkins H, Brignole M, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12: e41–e63. 10.1016/j.hrthm.2015.03.029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Raj S, Sheldon R. Management of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia and Vasovagal Syncope. Arrhythm Electrophysiol Rev. 2016;5: 122–129. 10.15420/AER.2016.7.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Pasaye EH, Gutiérrez RA, Alcauter S, Mercadillo RE, Aguilar-Castañeda E, DeIturbe M, et al. Event-Related Functional Magnetic Resonance Images during the Perception of Phantom Limb. A Brushing Task. Neuroradiol J. 2010;23: 665–670. 10.1177/197140091002300604 [DOI] [PubMed] [Google Scholar]
  • 39.Romero-Romo JI, Bauer CC, Pasaye EH, Gutiérrez RA, Favila R, Barrios FA. Abnormal functioning of the thalamocortical system underlies the conscious awareness of the phantom limb phenomenon. Neuroradiol J. 2010;23: 671–679. 10.1177/197140091002300605 [DOI] [PubMed] [Google Scholar]
  • 40.Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G, et al. International Chronic Fatigue Syndrome Study Group. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res. 2003;3: 25 10.1186/1472-6963-3-25 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Jones JF, Lin JM, Maloney EM, Boneva RS, Nater UM, Unger ER, et al. An evaluation of exclusionary medical/psychiatric conditions in the definition of chronic fatigue syndrome. BMC Med 2009;7: 57 10.1186/1741-7015-7-57 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Nater UM, Lin JM, Maloney EM, Jones JF, Tian H, Boneva RS, et al. Psychiatric comorbidity in persons with chronic fatigue syndrome identified from the Georgia population. Psychosom Med. 2009;71: 557–565. 10.1097/PSY.0b013e31819ea179 [DOI] [PubMed] [Google Scholar]
  • 43.Fappiano CM, Baraniuk JN. Gulf War Illness Symptom Severity and Onset: A Cross-Sectional Survey. Mil Med. 2020;2: usz471 10.1093/milmed/usz471 [DOI] [PubMed] [Google Scholar]
  • 44.Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Redefining an Illness. Report Guide for Clinicans. 2015. http://www.nationalacademies.org/hmd/~/media/Files/Report%20Files/2015/MECFS/MECFScliniciansguide.pdf. Accessed November 29, 2017
  • 45.Prager JM, Roychowdhury S, Gorey MT, Lowe GM, Diamond CW, Ragin A. Spinal headaches after myelograms: comparison of needle types. AJR Am J Roentgenol. 1996;167: 1289–1292. 10.2214/ajr.167.5.8911197 [DOI] [PubMed] [Google Scholar]
  • 46.Riley ET, Hamilton CL, Ratner EF, Cohen SE. A comparison of the 24-gauge Sprotte and Gertie Marx spinal needles for combined spinal-epidural analgesia during labor. Anesthesiology. 2002. September;97(3):574–7. Erratum in: Anesthesiology. 2003;98: 595. 10.1097/00000542-200209000-00009 [DOI] [PubMed] [Google Scholar]
  • 47.https://biocrates.com/absoluteidq-p180-kit/
  • 48.Mandal R, Guo AC, Chaudhary KK, Liu P, Yallou FS, Dong E, et al. Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update. Genome Med. 2012;4: 38 10.1186/gm337 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Koal T, Klavins K, Seppi D, Kemmler G, Humpel C. Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-β42, tau, and phospho-tau-181 levels. J Alzheimers Dis. 2015;44: 1193–1201. 10.3233/JAD-142319 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Cheema AK, Mehta KY, Fatanmi OO, Wise SY, Hinzman CP, Wolff J, et al. A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol. Int J Mol Sci. 2017;19: E79 10.3390/ijms19010079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Sheikh KD, Khanna S, Byers SW, Fornace A Jr, Cheema AK. Small molecule metabolite extraction strategy for improving LC/MS detection of cancer cell metabolome. J Biomol Tech. 2011;22: 1–4. [PMC free article] [PubMed] [Google Scholar]
  • 52.O'Donnell VB, Dennis EA, Wakelam MJO, Subramaniam S. LIPID MAPS: Serving the next generation of lipid researchers with tools, resources, data, and training. Sci Signal. 2019;12: eaaw2964 10.1126/scisignal.aaw2964 [DOI] [PubMed] [Google Scholar]
  • 53.https://www.lipidmaps.org/data/structure/index.php
  • 54.Boca SM, Sinha R, Cross AJ, Moore SC, Sampson JN. Testing multiple biological mediators simultaneously. Bioinformatics. 2014;30: 214‐220. 10.1093/bioinformatics/btt633 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Boca SM, Nishida M, Harris M, Rao S, Cheema AK, Gill K, et al. Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS One. 2016;11: e0153461 10.1371/journal.pone.0153461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Boca SM, Leek JT. A direct approach to estimating false discovery rates conditional on covariates. PeerJ. 2018;6: e6035 10.7717/peerj.6035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Ellis P. The Essential Guide to Effect Sizes: Statistical Power, Meta-Analysis, and the Interpretation of Research Results. Cambridge University Press, 2010 [Google Scholar]
  • 58.Jamieson AR, Giger ML, Drukker K, Li H, Yuan Y, Bhooshan N. Exploring nonlinear feature space dimension reduction and data representation in breast Cadx with Laplacian eigenmaps and t-SNE. Med Phys. 2010;37: 339–351. 10.1118/1.3267037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.https://cran.r-project.org/web/packages/Rtsne/Rtsne.pdf
  • 60.Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot Feasibility Stud. 2016;2: 64 10.1186/s40814-016-0105-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Holton K, Kirkland A, Brandley E, VanMeter J, Baraniuk J. The Low Glutamate Diet Significantly Improves Pain and Other Symptoms in Veterans with Gulf War Illness. Curr Dev Nutr. 2020;4(Suppl 2): 1211 10.3390/nu12092593 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Holton K. The role of diet in the treatment of fibromyalgia. Pain Manag. 2016;6: 317–320. 10.2217/pmt-2016-0019 [DOI] [PubMed] [Google Scholar]
  • 63.Holton KF, Taren DL, Thomson CA, Bennett RM, Jones KD. The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms. Clin Exp Rheumatol. 2012;30(6 Suppl 74): 10–7. [PubMed] [Google Scholar]
  • 64.Rodríguez A, Ortega A. Glutamine/Glutamate Transporters in Glial Cells: Much More Than Participants of a Metabolic Shuttle. Adv Neurobiol. 2017;16: 169–183. 10.1007/978-3-319-55769-4_8 [DOI] [PubMed] [Google Scholar]
  • 65.Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 2006;98: 641–653. 10.1111/j.1471-4159.2006.03913.x [DOI] [PubMed] [Google Scholar]
  • 66.Meyerhoff JL, Carter RE, Yourick DL, Slusher BS, Coyle JT. Genetically epilepsy-prone rats have increased brain regional activity of an enzyme which liberates glutamate from N-acetyl-aspartyl-glutamate. Brain Res. 1992;593: 140–143. 10.1016/0006-8993(92)91276-k [DOI] [PubMed] [Google Scholar]
  • 67.Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol. 2007;81: 89–131. 10.1016/j.pneurobio.2006.12.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Kuratsune H, Yamaguti K, Takahashi M, Misaki H, Tagawa S, Kitani T. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis. 1994;18(Suppl 1): S62–67. 10.1093/clinids/18.supplement_1.s62 [DOI] [PubMed] [Google Scholar]
  • 69.Reuter SE, Evans AM. Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity. J Intern Med. 2011;270: 76–84. 10.1111/j.1365-2796.2010.02341.x [DOI] [PubMed] [Google Scholar]
  • 70.Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology. 1995;32: 132–138. 10.1159/000119226 [DOI] [PubMed] [Google Scholar]
  • 71.Kuratsune H, Yamaguti K, Lindh G, Evengard B, Takahashi M, Machii T, et al. Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases. Int J Mol Med. 1998;2: 51–56. 10.3892/ijmm.2.1.51 [DOI] [PubMed] [Google Scholar]
  • 72.Soetekouw PM, Wevers RA, Vreken P, Elving LD, Janssen AJ, van der Veen Y, et al. Normal carnitine levels in patients with chronic fatigue syndrome. Neth J Med. 2000;57: 20–24. 10.1016/s0300-2977(00)00030-9 [DOI] [PubMed] [Google Scholar]
  • 73.Jones MG, Goodwin CS, Amjad S, Chalmers RA. Plasma and urinary carnitine and acylcarnitines in chronic fatigue syndrome. Clin Chim Acta. 2005;360: 173–177. 10.1016/j.cccn.2005.04.029 [DOI] [PubMed] [Google Scholar]
  • 74.Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, et al. Urinary excretion of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. J Nutr. 2011;141: 353–358. 10.3945/jn.110.135772 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.van der Velpen V, Teav T, Gallart-Ayala H, Mehl F, Konz I, Clark C, et al. Systemic and central nervous system metabolic alterations in Alzheimer's disease. Alzheimers Res Ther. 2019;11: 93 10.1186/s13195-019-0551-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.van der Hoek MD, Nieuwenhuizen AG, Kuda O, Bos P, Paluchová V, Verschuren L, et al. Intramuscular short-chain acylcarnitines in elderly people are decreased in (pre-)frail females, but not in males. FASEB J. 2020; Epub ahead of print. 10.1096/fj.202000493R [DOI] [PubMed] [Google Scholar]
  • 77.Romijn JA, Coyle EF, Sidossis LS, Gastaldelli A, Horowitz JF,et al. Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. Am J Physiol. 1993;265: E380–E391. 10.1152/ajpendo.1993.265.3.E380 [DOI] [PubMed] [Google Scholar]
  • 78.Zhang J, Light AR, Hoppel CL, Campbell C, Chandler CJ, Burnett DJ, et al. Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism, and potential signals to muscle afferent neurons. Exp Physiol. 2017;102: 48–69. 10.1113/EP086019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Féry F, Balasse EO. Ketone body turnover during and after exercise in overnight-fasted and starved humans. Am J Physiol. 1983;245: E318–E25. 10.1152/ajpendo.1983.245.4.E318 [DOI] [PubMed] [Google Scholar]
  • 80.Albaugh VL, Vary TC, Ilkayeva O, Wenner BR, Maresca KP, Joyal JL, et al. Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. Schizophrenia bulletin 2012;38: 153–166. 10.1093/schbul/sbq053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Vary TC, Lynch CJ. Meal feeding enhances formation of eIF4F in skeletal muscle: role of increased eIF4E availability and eIF4G phosphorylation. American journal of physiology Endocrinology and metabolism 2006;290: E631–642. 10.1152/ajpendo.00460.2005 [DOI] [PubMed] [Google Scholar]
  • 82.Kirwan JA, Brennan L, Broadhurst D, Fiehn O, Cascante M, Dunn WB, et al. Preanalytical Processing and Biobanking Procedures of Biological Samples for Metabolomics Research: A White Paper, Community Perspective (for "Precision Medicine and Pharmacometabolomics Task Group"-The Metabolomics Society Initiative). Clin Chem. 2018;64: 1158–1182. 10.1373/clinchem.2018.287045 [DOI] [PubMed] [Google Scholar]
  • 83.Gaschler MM, Stockwell BR. Lipid peroxidation in cell death. Biochem Biophys Res Commun. 2017;482: 419–425. 10.1016/j.bbrc.2016.10.086 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Pankaj K Singh

20 Oct 2020

PONE-D-20-29578

Metabolic biomarkers in cerebrospinal fluid from Gulf War Illness and Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

PLOS ONE

Dear Dr. Baraniuk,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Specifically, please improve the flow of the manuscript and provide additional descriptions for the points raised by the reviewers.

Please submit your revised manuscript by 1st April 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Pankaj K Singh, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1) Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2)  In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors compared the metabolic profiles in cerebrospinal fluid from ME/CFS and GWI and sedentary control after either rest or exercise. The study is concise and sound, but some minor revision should be corrected before further publication.

1. Line 266-272. It is confused that the authors compared the PC aa C42:6 levels between cfs0 and STOPP (GWI post exercise) groups, because multiple factors can contribute to the differences. Though GLM used, I think it is meaningless to compare these two groups.

2. Line 281, line 315-332. The explanation of C5-OH should be careful. The C5-OH, as the metabolite of leucine converted carnitine form is different from the long chain acylcarnitine. The elevation of acyl carnitine can also attributed to increased fatty acid oxidation after exercise (Metabolism. 2002 Apr;51(4):460-4.) The elevation of C5-OH may be the result of activated leucine metabolism. Previous study has showed the positive correlation between short chain acylcarnitine levels and physical performance (DOI: 10.1096/fj.202000493R).

3. The quality of figure 1 should be improved

Reviewer #2: The manuscript entitled “Metabolic biomarkers in cerebrospinal fluid from Gulf War Illness (GWI) and Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)” by Baraniuk et al submitted to PLOSOne highlighted the Dysfunction in lipid metabolism may distinguish ME/CFS from GWI. Although the manuscript addresses an important question, the manuscript is not written well, lack of coherence, less organized and difficult to follow. I recommend improving the overall presentation for publication.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dezhen Wang

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jan 13;16(1):e0244116. doi: 10.1371/journal.pone.0244116.r002

Author response to Decision Letter 0


31 Oct 2020

Reviewer #1: The authors compared the metabolic profiles in cerebrospinal fluid from ME/CFS and GWI and sedentary control after either rest or exercise. The study is concise and sound, but some minor revision should be corrected before further publication.

1. Line 266-272. It is confused that the authors compared the PC aa C42:6 levels between cfs0 and STOPP (GWI post exercise) groups, because multiple factors can contribute to the differences. Though GLM used, I think it is meaningless to compare these two groups.

Deleted.

2. Line 281, line 315-332. The explanation of C5-OH should be careful. The C5-OH, as the metabolite of leucine converted carnitine form is different from the long chain acylcarnitine. The elevation of acyl carnitine can also attributed to increased fatty acid oxidation after exercise (Metabolism 2002 Apr;51(4):460-4.). The elevation of C5-OH may be the result of activated leucine metabolism. Previous study has showed the positive correlation between short chain acylcarnitine levels and physical performance (DOI: 10.1096/fj.202000493R).

Thank you for the references regarding “Long- and medium-chain fatty acid oxidation is increased in exercise-trained human skeletal muscle” and “Low intramuscular levels of short-chain acylcarnitines have been found in older females compared to males”.

As a result, we investigated the C5-OH findings from 3 novel perspectives and added limitations and potential pitfalls:

Line 308 to 363:

Acylcarnitine C5-OH (C3-DC-M) was higher in postexercise SC than other groups. This suggested (i) no differences between nonexercise groups, (ii) effects of exercise (SC>sc0) and (iii) differences between postexercise SC and GWI groups. …

3. The quality of figure 1 should be improved

Figure 1 has reformatted. The Pearson correlation data for each group have been placed in Supplementary Information as Excel files. The 6 panels are now shown as individual color coded Excel sheets to show correlations for each metabolite.

Thank you for your recommendations.

Reviewer #2: The manuscript entitled “Metabolic biomarkers in cerebrospinal fluid from Gulf War Illness (GWI) and Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)” by Baraniuk et al submitted to PLOSOne highlighted the Dysfunction in lipid metabolism may distinguish ME/CFS from GWI. Although the manuscript addresses an important question, the manuscript is not written well, lack of coherence, less organized and difficult to follow. I recommend improving the overall presentation for publication.

We have had an external review of the paper, and have rewritten substantial portions. These are indicated by the highlighted sections of the revised manuscript.

The Introduction and Methods are redundant as they describe the 6 subgroups of subjects. We have reinforced the algorithm for assigning group and disease status because it is imperative to emphasize the objective route taken to define characteristics of each subgroup and then to generate new hypotheses to explain the diverse underlying pathological mechanisms.

The results and discussion have been edited as per Reviewer 1. This provides additional discussion of C5-OH, other acylcarnitines and potential dysfunction of metabolomics pathways.

Thank you for your recommendation.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Pankaj K Singh

3 Dec 2020

Exercise modifies glutamate and other metabolic biomarkers in cerebrospinal fluid from Gulf War Illness and Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

PONE-D-20-29578R1

Dear Dr. Baraniuk,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Pankaj K Singh, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: the authors have adequately addressed my comments raised in a previous round of review and I think this manuscript is now acceptable for publication

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dezhen Wang

Reviewer #2: No

Acceptance letter

Pankaj K Singh

23 Dec 2020

PONE-D-20-29578R1

Exercise modifies glutamate and other metabolic biomarkers in cerebrospinal fluid fromGulf War Illness and Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Dear Dr. Baraniuk:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Pankaj K Singh

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Raw data

    (XLSX)

    S1 Table

    (XLSX)

    S2 Table

    (XLSX)

    S3 Table

    (XLSX)

    S4 Table

    (XLSX)

    S5 Table

    (XLSX)

    S6 Table

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    The minimal data sets are attached as Excel sheets in the Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES